Stephens Inc’s Dyne Therapeutics DYN Stock Holding History

Stephens Inc’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,118	Closed	-$183K	–	1347
2026 Q1	$183K	Buy	+10,118	New	+$174K	﹤0.01%	1222

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Stephens Inc's DYN Position: Q2 2026 in Review

Stephens Inc sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 10,118 shares — an estimated $183K sold.

Stephens Inc first reported a position in DYN in Q1 2026 and held it in 1 quarter. The position peaked at $183K in Q1 2026. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Stephens Inc reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
Stephens Inc sold 10,118 Dyne Therapeutics shares in Q2 2026, an estimated $183K.
Stephens Inc first reported a position in Dyne Therapeutics in Q1 2026 and held it in 1 quarter.
Stephens Inc's Dyne Therapeutics position peaked at $183K in Q1 2026.
246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Stephens Inc's 13F filing for Q2 2026, filed 29 Jul 2026.